Novel |
TAF4 |
TATA-box binding protein associated factor 4 |
- HIV Transcription Initiation
- RNA Polymerase II HIV Promoter Escape
- Transcription of the HIV genome
- RNA Polymerase II Pre-transcription Events
- Regulation of TP53 Activity through Phosphorylation
- RNA Polymerase II Promoter Escape
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Initiation And Promoter Clearance
|
|
|
Novel |
TAL1 |
TAL bHLH transcription factor 1, erythroid differentiation factor |
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Transcriptional regulation of granulopoiesis
|
|
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
|
Novel |
TBP |
TATA-box binding protein |
- HIV Transcription Initiation
- RNA Polymerase II HIV Promoter Escape
- Transcription of the HIV genome
- SIRT1 negatively regulates rRNA expression
- NoRC negatively regulates rRNA expression
- B-WICH complex positively regulates rRNA expression
- RNA Polymerase II Pre-transcription Events
- Regulation of TP53 Activity through Phosphorylation
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Escape
- RNA Polymerase II Promoter Escape
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Transcription Termination
- RNA Polymerase III Abortive And Retractive Initiation
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- RNA Polymerase III Transcription Initiation From Type 1 Promoter
- RNA Polymerase III Transcription Initiation From Type 1 Promoter
- RNA Polymerase III Transcription Initiation From Type 2 Promoter
- RNA Polymerase III Transcription Initiation From Type 2 Promoter
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- Estrogen-dependent gene expression
|
|
- Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
|
Novel |
TLX3 |
T cell leukemia homeobox 3 |
|
|
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
|
Novel |
TP53 |
tumor protein p53 |
- Activation of NOXA and translocation to mitochondria
- Activation of PUMA and translocation to mitochondria
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Oncogene Induced Senescence
- DNA Damage/Telomere Stress Induced Senescence
- SUMOylation of transcription factors
- Autodegradation of the E3 ubiquitin ligase COP1
- Association of TriC/CCT with target proteins during biosynthesis
- Pyroptosis
- TP53 Regulates Metabolic Genes
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
- Regulation of TP53 Expression
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- Regulation of TP53 Activity through Methylation
- PI5P Regulates TP53 Acetylation
- G2/M DNA damage checkpoint
- G2/M Checkpoints
- Stabilization of p53
- Transcriptional activation of cell cycle inhibitor p21
- The role of GTSE1 in G2/M progression after G2 checkpoint
- Transcriptional Regulation by VENTX
- RUNX3 regulates CDKN1A transcription
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Loss of function of TP53 in cancer due to loss of tetramerization ability
- Signaling by ALK fusions and activated point mutants
- Regulation of NF-kappa B signaling
- Zygotic genome activation (ZGA)
- Factors involved in megakaryocyte development and platelet production
- PKR-mediated signaling
|
- Acetylsalicylic acid
- Zinc
- Triethyl phosphate
- AZD 3355
- 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Chronic myeloid leukemia (CML)
- Breast cancer
- Non-small cell lung cancer
- Gastric cancer
- Adult T-cell leukemia
- Choriocarcinoma
- Esophageal cancer
- Glioma
- Pancreatic cancer
- Vulvar cancer
- Multiple myeloma
- Choroid plexus papilloma
- Ovarian cancer
- Hepatocellular carcinoma
- Squamous cell carcinoma
- Endometrial Cancer
- Penile cancer
- Cancer of the anal canal
- Hairy-cell leukemia
- Oral cancer
- Adrenal carcinoma
- Malignant melanoma
- Burkitt lymphoma
- Thyroid cancer
- Basal cell carcinoma
- Small cell lung cancer
- Gallbladder cancer
- Bladder cancer
- Laryngeal cancer
- Kaposi's sarcoma
- Cholangiocarcinoma
- Chronic lymphocytic leukemia (CLL)
- Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
- Malignant pleural mesothelioma
- Osteosarcoma
- Colorectal cancer
|
Novel |
TP73 |
tumor protein p73 |
- Activation of PUMA and translocation to mitochondria
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- Regulation of TP53 Activity through Association with Co-factors
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
|
- Zinc
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
Novel |
TPI1 |
triosephosphate isomerase 1 |
- Glycolysis
- Gluconeogenesis
|
- Zinc
- N-Hydroxy-4-phosphonobutanamide
- 2-Phosphoglycolic Acid
- Phosphoglycolohydroxamic Acid
- 3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid
- [2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid
- 5-fluorotryptophan
- 2-Carboxyethylphosphonic Acid
- tert-butanol
- Dihydroxyacetone phosphate
- 1,4-Dithiothreitol
- 3-phospho-D-glyceric acid
- 3-(BUTYLSULPHONYL)-PROPANOIC ACID
- Artenimol
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Anemia due to disorders of glycolytic enzymes, including: Hexokinase (HK) deficiency; Phosphoglycerate kinase 1 (PGK1) deficiency; Triose-phosphate isomerase (TPI) deficiency; Glucose phosphate isomerase (GPI) deficiency; Bisphosphoglycerate mutase (BPGM) deficiency
|
Novel |
VEGFA |
vascular endothelial growth factor A |
- Platelet degranulation
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by VEGF
- VEGF ligand-receptor interactions
- VEGF binds to VEGFR leading to receptor dimerization
- Interleukin-4 and Interleukin-13 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
|
- Bevacizumab
- Minocycline
- Gliclazide
- Carvedilol
- Ranibizumab
- Pidolic acid
- Pegaptanib
- Vandetanib
- ABT-510
- Veglin
- Denibulin
- SNS-032
- Bevasiranib
- Dalteparin
- Aflibercept
- Chondroitin sulfate
- Foreskin keratinocyte (neonatal)
- Vanucizumab
- Brolucizumab
- Faricimab
|
|
Novel |
VHL |
von Hippel-Lindau tumor suppressor |
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- SUMOylation of ubiquitinylation proteins
- Neddylation
- Replication of the SARS-CoV-1 genome
- Replication of the SARS-CoV-2 genome
- RHOBTB3 ATPase cycle
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
- von Hippel-Lindau syndrome
- Congenital polycythemia; Familial erythrocytosis (ECYT)
- Renal cell carcinoma
|
Novel |
YY1 |
YY1 transcription factor |
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- UCH proteinases
- DNA Damage Recognition in GG-NER
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Estrogen-dependent gene expression
|
|
|
Novel |
ZBTB16 |
zinc finger and BTB domain containing 16 |
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
- Skeletal defects, genital hypoplasia, and mental retardation
- Acute myeloid leukemia (AML)
|
Novel |
ZBTB2 |
zinc finger and BTB domain containing 2 |
|
|
|
Novel |
ZBTB5 |
zinc finger and BTB domain containing 5 |
|
|
|
Novel |
ZBTB7A |
zinc finger and BTB domain containing 7A |
|
|
|
|
AATF |
apoptosis antagonizing transcription factor |
- NRAGE signals death through JNK
|
|
|
|
AHR |
aryl hydrocarbon receptor |
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
- Omeprazole
- Mexiletine
- Nimodipine
- Flutamide
- Atorvastatin
- Leflunomide
- Ginseng
- Indirubin-3'-monoxime
- Resveratrol
- Quercetin
- Tapinarof
- beta-Naphthoflavone
- Emodin
- 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
- Diosmin
- Kynurenic Acid
- Epigallocatechin gallate
- Cantharidin
- Indirubin
- Carbendazim
- Indigo
|
|
|
AKT1 |
AKT serine/threonine kinase 1 |
- Activation of BAD and translocation to mitochondria
- PIP3 activates AKT signaling
- PIP3 activates AKT signaling
- Downregulation of ERBB2:ERBB3 signaling
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- MTOR signalling
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the nucleus
- Negative regulation of the PI3K/AKT network
- eNOS activation
- AKT-mediated inactivation of FOXO1A
- Integrin signaling
- Deactivation of the beta-catenin transactivating complex
- CD28 dependent PI3K/Akt signaling
- Co-inhibition by CTLA4
- G beta:gamma signalling through PI3Kgamma
- Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
- KSRP (KHSRP) binds and destabilizes mRNA
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Interleukin-4 and Interleukin-13 signaling
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- RAB GEFs exchange GTP for GDP on RABs
- RUNX2 regulates genes involved in cell migration
- Regulation of PTEN stability and activity
- Extra-nuclear estrogen signaling
- Negative regulation of NOTCH4 signaling
- FLT3 Signaling
- Regulation of localization of FOXO transcription factors
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- KEAP1-NFE2L2 pathway
- SARS-CoV-2 targets host intracellular signalling and regulatory pathways
- Mitochondrial unfolded protein response (UPRmt)
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
|
- ATP
- Arsenic trioxide
- Genistein
- Inositol 1,3,4,5-Tetrakisphosphate
- Resveratrol
- Archexin
- Enzastaurin
- Perifosine
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
- PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
|
|
AR |
androgen receptor |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Ub-specific processing proteases
- RUNX2 regulates osteoblast differentiation
- RUNX2 regulates osteoblast differentiation
|
- Diethylstilbestrol
- Levonorgestrel
- Progesterone
- Spironolactone
- Flutamide
- Oxandrolone
- Fluphenazine
- Testosterone
- Mitotane
- Estrone
- Nilutamide
- Tamoxifen
- Norethisterone
- Drostanolone
- Norgestimate
- Nandrolone phenpropionate
- Ketoconazole
- Acetophenazine
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone propionate
- Oxybenzone
- 1-Testosterone
- Boldenone
- Calusterone
- Periciazine
- Prasterone
- Flufenamic acid
- Stanolone
- (R)-Bicalutamide
- Metribolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone acetate
- LGD2941
- Dimethylcurcumin
- Oxymetholone
- Methyltestosterone
- Norelgestromin
- Stanozolol
- Tetrahydrogestrinone
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- BMS-564929
- S-23
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- Andarine
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- LGD-2226
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Triclosan
- Nandrolone decanoate
- Ulipristal
- Enzalutamide
- Eugenol
- Dienogest
- Norethynodrel
- Norgestrel
- Homosalate
- Enzacamene
- Luprostiol
- Mibolerone
- Phenothiazine
- Gestrinone
- Apalutamide
- Clascoterone
- Darolutamide
- Esculin
- Ligandrol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Segesterone acetate
- Boldenone undecylenate
- Echinacoside
- Ketodarolutamide
|
- Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
- 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
- Prostate cancer
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
|
|
ARHGAP21 |
Rho GTPase activating protein 21 |
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- RND3 GTPase cycle
|
|
|
|
ARNT |
aryl hydrocarbon receptor nuclear translocator |
- Regulation of gene expression by Hypoxia-inducible Factor
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
|
|
|